Showcase the Broad Therapeutic Potential of HCB101 in Tumor Immunotherapy

• As the only innovative drug company from Taiwan invited to this year’s CBA Annual Conference, HanchorBio took the international stage to present its AI-assisted Structural Engineering on SIRP-alfa fusion biologic for enhancing Safety and Efficacy, marking an important milestone for Taiwan’s biotech industry.

• This recognition not only strengthens Taiwan’s position in global AI-assisted drug development, but also opens new opportunities for cross-border licensing and collaboration.

Registration: Eventbrite

October 2, 2025 – HanchorBio today announced that the company has been invited to participate in the 27^th Annual Conference of the Chinese Bioscience Association (CBA), to be held in Foster City, California, where it will present the broad therapeutic potential of its innovative drug candidate HCB101 in tumor immunotherapy.

Dr. Scott Liu, Founder, Chairman, and CEO of HanchorBio Inc., as a winner of the 2022 CABS K. Fong Award in Life Sciences for the outstanding contribution to the development of multiple biologic products from research to launch from the Chinese-American Biopharmaceutical Society (CABS) and will deliver a featured presentation titled “Engineering of SIRP-alpha through AI-assisted structural modeling for enhanced safety and efficacy” on October 4, 2025, from 15:35 to 16:00 PDT. The presentation will highlight how AI-assisted structural modeling can be applied to the engineering of SIRP-alpha, aiming to improve drug safety and efficacy, and will showcase the promise of HCB101 as a next-generation immunotherapy for cancer.

Event Information

• Conference Name: CBA Chinese Bioscience Association 27^th Annual Conference
• Theme: Charting new territories: advancing ADCs and Next-generation neurodegenerative therapies
• Date & Time: October 4, 2025, 15:35–16:00 PDT
• Location: Crowne Plaza Foster City-San Mateo (1221 Chess Drive, Foster City, CA 94404, United States)
• Presentation Title: Engineering of SIRP-alpha through AI-assisted structural modeling for enhanced safety and efficacy
• Speaker: Dr. Scott Liu, Chairman of HanchorBio

In recent years, the global biopharmaceutical industry has experienced unprecedented growth. With advances in science and the rising demand for healthcare, research and applications in the biopharmaceutical field have made remarkable progress. Breakthroughs in drug discovery, gene therapy, and cell therapy continue to emerge, injecting new momentum into the industry. Meanwhile, the market size of biopharma continues to expand, drawing increasing investment and global attention.

About the CBA 27^th Annual Conference

The CBA Annual Conference is a premier event for the global Chinese biopharmaceutical community, dedicated to fostering academic exchange, innovation, and international collaboration. This year’s conference, themed “Charting new territories: advancing ADCs and Next-generation neurodegenerative therapies”, will focus on key frontier topics, including:

• Global regulatory updates
• Innovations in technology and AI applications
• Breakthroughs in advanced therapeutics
• Strategies for drug discovery and development
• Emerging market opportunities and global expansion

About HanchorBio

HanchorBio is dedicated to developing innovative fusion protein biotherapeutics that harness the immune system to fight cancer. At the core of its innovation is the proprietary FBDB^TM platform, which enables the precise design of multi-target biologics within a single molecule, delivering both enhanced efficacy and improved safety. HanchorBio is committed to advancing next-generation immunotherapies, including HCB101, with the goal of addressing unmet medical needs and bringing transformative treatment options to cancer patients worldwide.

Registration: Eventbrite

漢康受邀登美國華人生物醫藥科技協會CBA年會 唯一代表台灣創新藥物公司

發表創新藥HCB101在腫瘤免疫治療的廣譜治療潛力

• 漢康為本次CBA年會中唯一受邀代表台灣的創新藥公司，登上國際舞台發表研發成果，樹立台灣生技產業的重要里程碑。

• 強化台灣在國際創新藥研發領域的地位，更開啟跨國授權與合作的新契機。

報名連結: Eventbrite

2025年10月2日 —— 漢康生技今日宣布，公司受邀參加將於美國加州福斯特城舉辦的 美國華人生物醫藥科技協會（Chinese Bioscience Association, CBA）第27屆年會，並發表其創新藥物 HCB101 在腫瘤免疫治療領域的廣譜治療潛力。

漢康生技董事長劉世高博士曾因「對多項生物藥從研發至上市的卓越貢獻」獲得2022年由美國華人生物製藥協會（CABS）頒發的 K. Fong Award in Life Sciences 殊榮，將於 2025年10月4日15:35–16:00（美西時間） 發表題為 「Engineering of SIRP-alpha through AI-assisted structural modeling for enhanced safety and efficacy」 的專題演講，重點介紹如何透過AI輔助結構建模進行SIRP-alpha工程化，以提升藥物安全性與療效，並展示HCB101作為新一代腫瘤免疫治療藥物的潛力。

活動資訊

• 會議名稱：CBA Chinese Bioscience Association 第27屆年會
• 主題：Charting new territories: advancing ADCs and Next-generation neurodegenerative therapies
• 時間：2025年10月4日 15:35–16:00（PDT）
• 地點：Crowne Plaza Foster City-San Mateo (1221 Chess Drive Foster City, CA 94404 United StatesFoster City, California, USA)
• 演講題目：Engineering of SIRP-alpha through AI-assisted structural modeling for enhanced safety and efficacy
• 主講人：劉世高 博士 (Scott Liu)，漢康生技董事長

近年來，全球生物醫藥行業經歷了前所未有的快速發展。隨著科技的進步和人們對健康需求的不斷提升，生物醫藥領域的研究和應用取得了顯著進展。新藥研發、基因治療、細胞治療等前沿技術不斷湧現，為生物醫藥行業的發展注入了新的活力。同時，生物醫藥行業的市場規模也在不斷擴大，吸引了越來越多的投資和關注。

關於CBA第27屆年會

CBA年會是全球華人生物醫藥界的重要盛會，致力於促進學術與產業交流，推動創新與國際合作。本屆年會以「Charting new territories: advancing ADCs and Next-generation neurodegenerative therapies」 為主題，聚焦以下前沿議題：

• 全球監管新動態
• 技術與AI革新應用
• 先進治療技術突破
• 藥物創新開發策略
• 新興市場與國際佈局

關於漢康生技

漢康生技專注於研發針對癌症的創新融合蛋白藥物，並以自主 FBDB^TM平台 為核心，能將多重靶點精準設計於單一分子中，提升治療效果與安全性。公司致力於開發新一代腫瘤免疫治療藥物，如HCB101, HCB301等，持續推動創新醫藥的臨床應用，期望為全球癌症患者帶來突破性的治療選擇。

報名連結: Eventbrite